IDEXX Laboratories Announces Agreement to Utilize Philips Digital Pathology Solution VET
WESTBROOK, Maine, August 26, 2014—IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced today that it has entered into an agreement with Royal Philips (NYSE: PHG, AEX: PHIA), under which the company will use the Philips Digital Pathology Solution VET in IDEXX Reference Laboratories to digitize veterinary histopathology images. Creating a virtual digital pathology network will reduce turnaround time and provide even better service to practicing veterinarians around the world.
“The Philips pathology slide scanner and viewer allows us to leverage the expertise of our global veterinary pathologists in real time, and operationally integrates within our Lean Six Sigma practices,” said Jeremy Johnson, head of IDEXX North America Anatomic Pathology and Histology. “It also provides real-time pathologist-to-pathologist collaboration, regardless of location, which enables us to provide veterinary pathology services that exceed our customers’ expectations.”
The Philips Digital Pathology Solution VET will streamline IDEXX veterinary pathology and histology operations, improving turnaround time for customers. The use of web-based tools will provide flexibility in day-to-day operations and give veterinarians convenient access to subject-matter experts within IDEXX Reference Laboratories’ centers of excellence, including oncology, dermatology and immunohistochemistry, as well as avian and exotics.
“The digital revolution in health care has enabled new ways of improving medical outcomes at lower costs,” said Perry van Rijsingen, general manager, Philips Digital Pathology Solutions. “With the Philips Digital Pathology Solution VET for veterinary use, IDEXX is now implementing the latest innovations with the aim of further enhancing the health and well-being of pets and livestock.”
This agreement to use the Philips Digital Pathology Solution VET in IDEXX Reference Laboratories represents the most recent development in the long-standing partnership between Royal Philips and IDEXX Reference Laboratories.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,900 people and offers products to customers in over 175 countries.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of health care, consumer lifestyle and lighting. Headquartered in the Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs approximately 112,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home health care, energy-efficient lighting solutions and new lighting applications, as well as male shaving and grooming, and oral healthcare. News from Philips is located at philips.com/newscenter.
Note Regarding Forward-Looking Statements
This news release contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,” “would,” “will,” “plans,” “believes,” “estimates,” “should,” and similar words and expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available from the SEC's EDGAR database at sec.gov, at various SEC reference facilities in the United States and via the Company's website at idexx.com).